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Background: We conducted a prospective, observational study in Barcelona to determine the epidemiology,
clinical features, and outcome of elderly patients with acute bacterial meningitis (ABM) compared with younger
adults.
Methods: During 1982–2010, all patients with ABM were prospectively evaluated. There were two groups: I
(15–64 years) and II (≥ 65 years). All patients underwent clinical examination on admission and at discharge
following a predefined protocol.
Results: We evaluated 635 episodes of ABM. The incidence was 4.03/100,000 (Group I) and 7.40 /100,000 inhabitants/
year (Group II) (RR = 1.84; 95%CI: 1.56–2.17, P < 0.0001). Elderly patients had co-morbid conditions more frequently
(P < 0.0001) and more frequently lacked fever (P = 0.0625), neck stiffness (P < 0.0001) and skin rash (P < 0.0001), but had
an altered level of consciousness more often (P < 0.0001). The interval admission-start of antibiotic therapy was longer
for elderly patients (P < 0.0001). Meningococcal meningitis was less frequent in elderly patients (P < 0.0001), whereas
listerial (P = 0.0196), gram-negative bacillary (P = 0.0065), and meningitis of unknown origin (P = 0.0076) were more
frequent. Elderly patients had a higher number of neurologic (P = 0.0009) and extra-neurologic complications
(P < 0.0001). The overall mortality ratio was higher in elderly patients (P < 0.0001).
Conclusions: Elderly people are at higher risk of having ABM than younger adults. ABM in the elderly presents with
co-morbid conditions, is clinically subtler, has a longer interval admission-antibiotic therapy, and has non-meningococcal
etiology. It is associated with an earlier and higher mortality rate than in younger patients.
Keywords: Bacterial meningitis, Acute, Elderly, Streptococcus pneumoniae, Listeria monocytogenes, Co-morbidities,
Outcome, Complications, Post-meningitic sequelaeBackground
During the past years we have witnessed significant
changes in the epidemiology of ABM. The most import-
ant change is the dramatic decline of incidence of men-
ingitis due to Haemophilus influenzae serotype b (Hib)
due to infant vaccination [1,2], and the striking decrease
of early-onset disease caused by group B Streptococcus
because of use of intra-partum antibiotic prophylaxis [3].
The incidence and pattern of many infectious diseases
vary over time. These changes are due to many factors,
but among them modifications in the population* Correspondence: pdomingo@santpau.cat
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reproduction in any medium, provided the orstructure stand out. Population structure in developed
countries is continuously changing, and this change is
mainly driven by two factors; first, the continuing aging
of native population, and second the incoming migratory
fluxes from developing countries. However, most likely
the first one is still predominant and, therefore, elderly
people are one of the fastest-growing segments in most
western societies. The incidence of meningeal pathogen
infections is highly influenced by the age of the patient,
and ABM is considered a disease of extreme ages of
life [4].
The aim of our study was to determine the spectrum
of ABM in elderly patients over the last 30 years,
compared to a younger population from the same geo-
graphical area, both recruited from a community univer-
sity hospital in Barcelona (Spain).ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study population
We used data from a large, prospective, single-hospital
cohort of patients with ABM enrolled over a 30-year
period at the Hospital de la Santa Creu i Sant Pau (Bar-
celona, Spain). Our institution is a 620-bed tertiary uni-
versity hospital providing care for an urban area with a
population of 441,392 inhabitants. From 1982 to 2010
all consecutive adults with ABM diagnosed at our Hos-
pital were prospectively identified and followed. The
study was approved by the Ethics Committee of the Hos-
pital de la Santa Creu I Sant Pau.
Diagnosis of acute bacterial meningitis
The diagnosis of ABM caused by a specific bacterial
pathogen was based on the presence of consistent clinical
findings (sudden onset of headache, fever, nausea,
vomiting, neck stiffness and/or altered mental status) and
one of the following: a positive cerebrospinal fluid (CSF)
culture; or a negative CSF culture with a finding of pleocy-
tosis and at least one of the following: a positive CSF anti-
gen test, a positive blood culture, or identification of
gram-negative diplococci on Gram stain of CSF in patients
with a petechial or purpuric rash and a fulminant course.
These last cases were considered to be caused by Neisseria
meningitidis [5]. Episodes of ABM without etiologic diag-
nosis were included if patients had a consistent clinical
picture and CSF cyto-biochemical findings consistent with
purulent meningitis (pleocytosis of more than 5 poly-
morphonuclear leukocytes/mm3, hypoglycorrachia defined
as a CSF/blood glucose ratio < 0.50 and high CSF protein
defined as more than 45 mg/dl) despite negative blood
and negative CSF Gram stain and cultures [6,7]. Patients
with viral, fungal, or mycobacterial meningitis or a history
of neurosurgical procedures or traumatic head/spinal in-
jury were excluded.
From each episode, the following data were collected: sex,
age, underlying conditions, co-morbidity and co-morbidity
scoring according to the Charlson index, clinical cha-
racteristics, laboratory and microbiologic results (isolates
and susceptibility tests), complications, treatment, and out-
come. Data were collected during the index hospitalization,
and each patient was seen on admission and followed after
discharge by one of the authors (PD or VP).
Microbiologic methods
Isolates were obtained from routine cultures and were iden-
tified using standard methods [8]. The disc diffusion suscep-
tibility test was performed according to Clinical Laboratory
Standards Institute (CLSI) guidelines [9], using commer-
cially available discs (Bio-Rad™, Marnes La Coquette,
France). MICs were determined using the broth micro dilu-
tion method according to the CLSI guidelines [10] using
commercial panels (Sensitre,™ Trek diagnostic systems,West Sussex, England) or Etest™ (AB Biodisk, Solna,
Sweden) according to the recommendations of the manu-
facturer. Resistance breakpoints for penicillin were MIC ≥
0.12 mg/L for pneumococcus and meningococcus [11].
Definitions
A subject aged > 14 years was considered an adult and
when aged ≥ 65 years, elderly. Pre-admission receipt of
adequate antibiotic therapy has been previously defined
[12]. The interval from onset of symptoms and signs of
ABM until admission was the interval symptoms-
admission (ISA), whereas that from admission to the
first dose of antibiotic for ABM treatment was the inter-
val admission-therapy (IAT). Co-morbid conditions were
considered to be present if the patient had a confirmed
diagnosis of one or more of the following: cancer, sys-
temic vasculitides, cirrhosis of the liver, diabetes, chronic
renal failure, human immunodeficiency virus infection,
heart failure, and chronic pulmonary disease [12]. Alco-
hol abuse was defined when alcohol intake was > 40 g
daily [13]. Co-morbidity was graded according to the
Charlson Co-morbidity Scale [14].
Extra-meningeal infection was considered when a pa-
tient had a focal infection distant from the Central Ner-
vous System and the same pathogenic bacterium was
isolated from the primary focus or from blood culture
[15]. Appropriate antibiotic therapy was defined as admin-
istration of one or more antimicrobial agents shown to be
effective against the meningeal pathogen, which achieve
adequate CSF concentrations, commenced on admission
or before neurological or systemic deterioration in
inpatients [16]. Impaired mental status, seizures and focal
neurologic signs after the first dose of antibiotics were
considered neurological complications. The development
of septic shock, acute respiratory failure, renal failure,
and/or consumption coagulopathy was considered as
extra-neurological complications if related to ABM and
apparent on admission or shortly afterwards [17-22].
Nosocomial meningitis was defined as that developing
more than 48 hours after admission or within one week
after discharge from the hospital [23]. Coma has been
defined elsewhere [17]. Inpatient deaths were considered
due to ABM when meningitis was the underlying and im-
mediate cause of death. Causes of death were classified in
two categories: neurological causes or systemic causes
[18,23]. ABM was not considered to be the underlying
cause of death if a disease process unrelated to meningitis
began > 24 h after meningitis resolution and if it initiated
the train of morbid events leading to death [23]. Sequelae
were defined as previously outlined [12].
Statistical analysis
Continuous variables were compared using Student’s t-test
or the Mann–Whitney U test when appropriate. To
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plus the 95% CI, we used a Poisson model. We analyzed
categorical data using the χ2 test or Fisher’s exact test when
indicated. Survival curves in younger patients and in those
older than 65 years were compared by means of the
logrank test. Statistical analyses were performed using
Statistical Product and Service Solutions (SPSS) software
version 16 (SPSS Inc., Chicago, IL).
Results
Population studied
From 1982 to 2010, 635 episodes of ABM were
diagnosed in 623 adult patients, 427 in patients aged
15–64 years (Group I) and 208 in patients aged ≥ 65 years
(Group II). The corresponding incidence was 4.03/
100,000 and 7.40/100,000 inhabitants/year for group ITable 1 Demographics of patients with acute bacterial menin
Group I (non-elderly)
N = 427
Age (yrs) 32.0 (22.0–54.0)
15–24 yrs (%) 134 (31.4)
25–34 yrs (%) 59 (13.8)
35–44 yrs. (%) 60 (14.0)
45–54 yrs (%) 77 (18.0)
55–64 yrs (%) 97 (22.7)
≥ 65 yrs (%) ——
Male (%) 205 (48.0)
Co-morbidity (%) 168 (39.3)
Cancer† (%) 46 (10.8)
Alcohol abuse (%) 43 (10.1)
Liver cirrhosis (%) 15 (3.5)
Diabetes mellitus (%) 35 (8.2)
Chronic lung disease‡ (%) 11 (2.6)
Chronic cardiovascular disease§ (%) 15 (3.5)
Chronic renal failure (%) 17 (4.0)
Chronic debilitating diseases¶ (%) 8 (1.9)
Immunosuppressionll (%) 60 (14.0)
Charlson Index ≥ 1 134 (31.4)
0 (%) 283 (68.6)
1–2 (%) 87 (20.4)
3–4 (%) 22 (5.1)
≥ 5 (%) 25 (5.8)
Nosocomial acquisition (%) 14 (3.3)
Recurrent meningitis (%) 18 (4.2)
Values expressed as median and interquartile range unless otherwise specified.*Pat
(9), lung (6), breast (6), cavum (6), prostate (4), colon (3), endometrium (2), pharynx
endometrial (1), cervix (1), sphenoidal sinus (1), oesophagus (1), gastric (1), and vag
lymphoma (3), non-Hodgkin’s lymphoma (6), acute leukemias (8), chronic leukemias
(4), idiopathic pulmonary fibrosis (2), other pneumopathies (2) § Includes: arterial hy
valvular disease (8), chronic arrythmias (3), and Buerguer ‘s disease (1). ¶Include: pri
cerebral palsy (2), chronic hydrocephalus (2), amyloidosis (1). llIncludes: antineoplast
therapy (21), AIDS (6), splenectomy (6), hypocomplementemia (5), neutropenia (4),and II, respectively (RR = 1.84; 95% CI: 1.56–2.17, P <
0.0001). The median yearly number of cases was 21
(95% CI: 19–25). Demographics of the population stud-
ied are summarized in Table 1. Elderly population had
co-morbid conditions more frequently (Table 1). Co-
morbidity predisposing to ABM was outstandingly fre-
quent in meningitis by Listeria monocytogenes (87.4%)
compared with other etiologies (43.4%) (RR = 1.55, 95%
CI: 1.24–1.93, P = 0.0006). There were no statistically
significant differences between patients from both
groups in terms of gender, recurrence, and place of ac-
quisition of ABM (Table 1).
Clinical features
The clinical features of patients with ABM are
summarized in Table 2. Patients from group II had agitis according to age group*
Group II (elderly) RR (95% CI) P value
N = 208






208 (100) —— ——
99 (47.6) 0.99 (0.79–1.24) 0.9895
148 (71.1) 2.49 (1.93–3.22) < 0.0001
40 (19.2) 1.52 (1.17–1.97) 0.0051
21 (7.1) 1.00 (0.69–1.45) 0.8963
8 (3.8) 1.06 (0.60–1.88) 0.9878
46 (22.1) 1.94 (1.54–2.44) < 0.0001
25 (12.0) 2.27 (1.27–2.91) < 0.0001
59 (28.6) 3.00 (2.51–3.59) < 0.0001
21 (10.1) 1.76 (1.29–2.40) 0.0041
17 (8.2) 2.17 (1.62–2.91) 0.0003
42 (20.2) 1.36 (1.04–1.77) 0.0428
136 (65.4) 2.55 (2.00–3.24) < 0.0001
72 (34.6) 0.42 (0.33–0.53) < 0.0001
80 (38.5) 1.75 (1.41–2.17) < 0.0001
42 (20.2) 2.26 (1.81–2.81) < 0.0001
14 (5.7) 1.10 (0.71–1.70) 0.7984
11 (5.3) 1.36 (0.86–2.15) 0.3149
10 (4.8) 1.09 (0.66–1.82) 0.8924
ients may have more than a co-morbid condition. † includes: Solid (53): brain
(2), ovarian (2), urinary bladder (2), pleural mesothelioma (2), skin (2), testes (1),
ina (1), and haematological (33) cancers: multiple myeloma (8), Hodgkin’s
(7), and Waldenström disease (1). ‡ Includes: chronic bronchitis (28), asthma
pertension (40), coronary heart disease (18), congestive heart failure (15),
or stroke (9), senile dementia (7), hyperthyroidism (3), hypothyroidism (2),
ic chemotherapy (49), hypogammaglobulinemia (22), chronic corticosteroid
and radiotherapy (4).
Table 2 Clinical features of patients with acute bacterial meningitis according to age group*
Group I (non-elderly) Group II (elderly) RR (95% CI) P value
N = 427 N = 208
Interval symptoms-admission (hrs) 24.0 (24.0–37.0) 27.5 (24.0–37.0) —— 0.3822
Prior antimicrobial therapy (%) 126 (29.5) 77 (37.0) 1.25 (1.00–1.57) 0.0696
Extrameningeal infection† (%) 96 (22.5) 79 (37.9) 1.61(1.29–2.00) < 0.0001
Pneumonia (%) 17 (4.0) 20 (9.6) 1.72 (1.25–2.37) 0.0077
ENT infection (%) 56 (8.8) 33 (5.2) 1.16 (0.86–1.56) 0.4149
Urinary tract infection (%) 9 (1.4) 18 (2.8) 2.13 (1.59–2.86) 0.0003
Fever (%) 412 (96.5) 193 (92.8) 0.64 (0.44–0.93) 0.0625
Level of consciousness (%)
Normal (%) 174 (40.7) 49 (23.6) 0.57 (0.43–0.75) < 0.0001
Abnormal (%) 229 (62.6) 142 (68.3) 1.53 (1.20–1.93) 0.0006
Coma (%) 24 (5.6) 17 (8.2) 1.39 (0.95–2.04) 0.1639
Neck stiffness (%) 357 (83.6) 129 (62.0) 0.50 (0.41–0.62) < 0.0001
Meningeal triad present (%) 208 (48.7) 104 (50.0) 1.04 (0.83–1.29) 0.8275
Skin rash (%) 153 (35.8) 19 (9.1) 0.27 (0.17–0.62) < 0.0001
Interval admission-therapy (hrs) 3.0 (1.0–6.0) 4.0 (2.0–12.0) —— < 0.0001
Focal neurologic signs on admission (%) 63 (14.7) 43 (20.7) 1.30 (1.00–1.69) 0.0777
Seizures on admission (%) 33 (7.7) 13 (6.2) 0.85 (0.53–1.37) 0.6091
Cerebral computed tomography (%) 163 (57.8) 113 (75.8) 1.55 (1.24–1.93) 0.0002
Values expressed as median and interquartile range unless otherwise specified. ENT = ear, nose and throat. *A patient may have more than an extrameningeal
focus of infection. † Includes: otiitis (73), pneumonia (37), urinary tract infection (27), paranasal sinusitis (23), endocarditis (7), pyelonephritis (4), acute bronchitis
(4), tonsillitis (3), parappharyngeal abscess (2), cholecystitis (2), peritonitis (2), ventriculo-peritoneal shunt (2), dental abscess (2), scrotal abscess (1), psoas abscess
(1), i.v. catheter (1), pacemaker electrode infection (1).
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having received out-of-hospital antibiotic therapy. An
extra-meningeal focus of infection was found more fre-
quently in patients from group II, and this was especially
true for pneumonia and infra-diaphragmatic foci of in-
fection (RR = 1.66; 95% CI: 1.20–2.29, P = 0.0126). Eld-
erly patients more frequently lacked fever (although the
difference did not reach statistical significance), neck
stiffness and skin rash, but had an altered level of con-
sciousness more often (Table 2). Despite being brought
to the hospital with an interval similar to that of younger
patients, elderly patients suffered a greater delay from
arrival to the hospital to starting antibiotic therapy.
Cerebral computed tomography (CT) on admission was
performed in 163 (57.8%), and 113 (75.8%) patients from
groups I and II, respectively (Table 2).
CSF findings, microbiologic features and etiology
CSF cyto-biochemical and microbiological findings are
summarized in Table 3. CSF protein content was signifi-
cantly higher in patients from group II whereas they had
a lower diagnostic yield for the CSF Gram-stained
smear. The median CSF/blood glucose ratio was not
statistically different for immunosuppressed and im-
munocompetent patients after excluding diabeticpatients (0.240 {Interquartile range: 0.091–0.405} vs.
0.220 {IQR: 0.0070–0.440}, P = 0.5402). The median CSF
cell count in immunosuppressed patients was 560 cells/
mm3 (IQR: 173–1891) whereas in immunocompetent
patients it was 1178 (IQR: 327–3036) cells/mm3 (P =
0.0029). Blood cultures were most frequently positive in
elderly patients, although the difference did not reach
statistical significance. Meningococcal meningitis was
diagnosed less frequently whereas pneumococcal menin-
gitis was diagnosed more often in the elderly, although
the former difference was not statistically significant.
Listerial meningitis, gram-negative bacillary meningitis,
and meningitis of unknown origin also showed increases
in group II (Table 3). Meningococcal isolates from elderly
patients showed decreased susceptibility to penicillin more
frequently (27.3% vs. 5.5%, RR = 1.57; 95% CI: 0.99–2.47,
P = 0.0025), whereas penicillin-resistant pneumococcal
isolates were evenly distributed between both groups
(14.3% vs. 11.9%, RR = 1.09; 95% CI: 0.41–1.69, P = 0.8771).
The percentage of serogroup C meningococcal isolates fell
from 45.8% to 11.1% before and after the vaccination cam-
paign of the year 2000 (RR = 0.25; 95% CI: 0.08–0.75 P =
0.0050). Similarly, pneumococcal serotypes included in the
heptavalent vaccine fell from 38.4% to 22% after 2001
(OR = 2.21; 95% CI: 0.99–5.09, P = 0.0539).
Table 3 CSF findings, microbiologic features and etiology of acute bacterial meningitis according to age group
Group I (non-elderly) Group II (elderly) RR (95% CI) P value
N = 427 N = 208
CSF findings
Protein content, g/l 3.2 (1.5–6.5) 3.8 (1.8–7.3) —— 0.0306
mg/dl 320 (150–650) 380 (180–730)
CSF/plasma glucose ratio 0.24 (0.07–0.45) 0.22 (0.08–0.42) —— 0.7681
Cells/mm3 1022 (301–2993) 1026 (290–2968) —— 0.7490
Predominance PML † 385 (94.4) 183 (91.5) 0.76 (0.52–1.11) 0.2446
Positive CSF Gram stained smear (%) 199 (46.6) 68 (32.7) 0.67 (0.52–0.85) 0.0012
Positive CSF culture (%) 309 (72.4) 141 (67.8) 0.87 (0.68–1.09) 0.2721
Positive blood culture (%)‡ 184 (43.4) 104 (51.5) 1.25 (1.00–1.58) 0.0616
Etiology §
Meningococcal (%) 179 (41.9) 24 (11.5) 0.28 (0.19–0.41) < 0.0001
Pneumococcal (%) 91 (21.3) 59 (28.4) 1.28 (1.01–1.63) 0.0622
Listerial & grampositive bacilli (%) 33 (7.7) 29 (13.9) 1.93 (1.12–2.01) 0.0196
Other Gram-positive cocci (%) 22 (5.1) 13 (6.2) 1.14 (0.73–1.79) 0.7012
Gram-negative bacilli (%) 18 (4.2) 21 (10.1) 1.72 (1.25–2.35) 0.0065
Haemophilus influenzae (%) 9 (2.1) 5 (2.4) 1.09 (0.54–2.23) 0.9685
Mixed (%) 2 (0.5) 2 (1) 1.53 (0.57–4.11) 0.8393
Other 2 (0.5) 1 (0.5) 1.02 (0.20–5.06) 0.5517
Unknown origin (%) 71 (16.5) 54 (25.9) 1.43 (1.12–1.82) 0.0076
Values expressed as median and interquartile range unless otherwise specified. CSF = cerebrospinal fluid. PML polymorphonuclear leukocytes. † Differential count
performed in 608 patiens. ‡Blood culture performed in 624 patients. § Gram-positive bacilli: Listeria monocytogenes (60) and Bacillus cereus (2). Gram-positive cocci:
Staphylococcus aureus (12), Streptococcus agalactiae (8), Streptococcus viridans (4), Streptococcus pyogenes (3), Enterococcus faecalis (2), Staphylococcus epidermidis
(2), Streptococcus anginosus (1), Staphylococcus sp. (1), Group G streptococcus (1), Streptococcus bovis (1). Gram-negative bacilli: Escherichia coli (17), Pseudomonas
aeruginosa (8), Pseudomonas sp. (3), Serratia sp. (2), Klebsiella sp. (2), Proteus mirabilis (2), Serratia marcescens (1), Acinetobacter baumanii (1), Bacteroides
melaninogenicus (1), and Citrobacter freundii (1), and Enterobacter cloacae (1). Mixed meningitis: Bacteroides intermedius + Streptococcus viridans (1), Enterobacter
cloacae + Streptococcus viridans (1), Peptostreptococcus sp. + anaerobic unidentified GNB (1), and Peptostreptococcus sp. + Bacteroides sp. (1). Other: Brucella sp. (2)
and Neisseria subflava (1).
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Elderly patients developed more frequently coma, and
cranial nerve palsies of new appearance. Patients from
group II also developed acute respiratory failure and
acute renal failure more frequently (Table 4). Almost
90% of patients in each group received adequate empiric
antibiotic therapy.
The overall mortality ratio was significantly higher for
patients in group II (29.8% vs. 11.7%) (Table 4). This
higher mortality rate was caused by a higher mortality
rate of pneumococcal and of meningitis of unknown
origin. Survival curves for both groups of patients
showed an earlier probability of death for elderly
patients (Figure 1). When death directly attributable
to ABM was considered, the probability of dying was
again higher for elderly patients. Development of
complications conveyed higher rates of mortal-
ity in both groups, without statistically significant
differences between them (Table 5). There were no
differences between groups with respect to post-
meningitic sequelae.Discussion
Our study shows that elderly patients are at much higher
risk of developing ABM than younger adults. We also
observed a change in the etiology of the disease, Neisseria
meningitidis ranked first for younger patients, whereas it
was surpassed by pneumococcal, listerial, and meningitis
of unknown origin in the elderly. Another important, al-
though expectable, change is the increased prevalence of
co-morbid conditions among elderly people. This may
have an impact, not only on the etiology of ABM, but also
on the rate of complications and eventually on mortality.
Other differing findings for elderly people include a higher
chance of having received out-of-hospital antibiotic ther-
apy, more frequently lacking fever, neck stiffness and
skin rash, developing neurologic and extra-neurologic
complications more frequently, and having an increased
risk of death because of ABM. In summary, the linkage
and interaction of higher co-morbidity, different etiologic
spectrum, more pre-admission antibiotic therapy and sub-
tler clinical manifestations may contribute to explain most
of the differences between elderly and younger patients.
Table 4 Evolving features and outcome of acute bacterial meningitis according to age group*
Group I (non-elderly) Group II (elderly) RR (95% CI) P value
N = 427 N = 208
Neurologic complications (%) 80 (18.7) 64 (30.8) 1.52 (1.21–1.90) 0.0009
New focal neurologic signs (%) 23 (5.4) 16 (7.7) 1.27 (0.86–1.89) 0.3372
Coma (%) 57 (13.3) 48 (23.1) 1.51 (1.18–1.94) 0.0028
Seizures (%) 46 (10.7) 33 (15.9) 1.33 (1.00–1.77) 0.0897
New cranial palsies (%) 17 (4.0) 17 (8.2) 1.57 (1.10–2.25) 0.0439
Extra-neurologic complications (%) 109 (25.5) 94 (45.2) 1.75 (1.41–2.18) < 0.0001
Septic shock (%) 65 (15.2) 35 (16.8) 1.08 (0.80–1.44) 0.7125
Acute respiratory failure (%) 60 (14.0) 46 (22.1) 1.42 (1.10–1.82) 0.0145
Acute renal failure (%) 40 (9.4) 48 (23.1) 1.86 (1.48–2.35) < 0.0001
Consumption coagulopathy (%) 39 (9.1) 15 (7.2) 0.84 (0.54–1.31) 0.5071
Therapeutics
Adequate empiric antibiotic therapy (%) 398 (93.2) 187 (89.9) 0.76 (0.54–1.08) 0.1956
Dexamethasone therapy (%) 142 (33.2) 83 (39.9) 1.21 (0.97–1.52) 0.1198
Vasoactive drugs (%) 69 (16.1) 38 (18.3) 1.10 (0.83–1.46) 0.5797
Mechanical ventilation (%) 67 (15.7) 39 (18.7) 1.15 (0.87–1.52) 0.3915
Dialysis (%) 9 (2.1) 8 (3.8) 1.45 (0.87–2.44) 0.3116
Outcome
Overall mortality rate (%) 50 (11.7) 62 (29.8) 1.98 (1.60–2.46) < 0.0001
Meningococcal (%) 8 (4.5) 3 (12.5) 2.49 (0.88–7.10) 0.2494
Pneumococcal (%) 14 (15.0) 19 (31.7) 1.68 (1.14–2.48) 0.0259
Listerial & grampositive bacilli (%) 7 (21.2) 9 (31.0) 1.29 (0.75–2.23) 0.5544
Other grampositive cocci (%) 9 (40.9) 6 (46.1) 1.14 (0.48–2.70) 0.9597
Gramnegative bacilli (%) 10 (55.5) 12 (57.1) 1.03 (0.57–1.86) 0.8225
Haemophilus influenzae (%) 1 (11.1) 0 (0.0) 1.50 (0.30–7.43) 0.7320
Mixed (%) 0 (0.0) 0 (0.0) —— ——
Other 0 (0) 0 (0.0) —— ——
Unknown etiology (%) 1 (1.4) 13 (24.1) 2.51 (1.89–3.34) 0.0002
Death attributable to meningitis (%) 42 (9.8) 43 (20.7) 1.67 (1.30–2.13) 0.0004
Post-meningitic sequelae† (%) 42 (11.1) 21 (14.4) 1.22 (0.83–1.78) 0.3945
Values expressed as median and interquartile range unless otherwise specified. *A patient may have more than one complication or sequelae. † Sequelae: total or
partial deafness (19), limb palsy (18), cranial nerve palsy (13), memory disturbances (10), vegetative state (5), speech disturbances (4), polyneuritis (3), blindness (3),
bilateral leg amputation (2), seizures (2), myoclonia (2), hydrocephalus (1), chronic leg ulcers (1), long-term tracheostomy (1), and chronic renal failure (1).
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study is based on a single hospital and this may imply
that the results may only be applicable to places with a
population structure and local ecology similar to ours.
However, changes in the spectrum of ABM similar to
those observed in our study have been described, espe-
cially those referring to the epidemiology of meningo-
coccal disease [2,24-26]. Moreover, the pattern of
population change documented in Spain, has also been
reported in other Western, mainly European countries
[27]. Therefore, the population scenario may resemble
that described in the present work. Our study spans over
a long period of time; during 30 years it is obvious thatthe treatment and management of critically ill patients
and of ABM have changed a lot. Although the case rec-
ord forms were standardized and remained the same
throughout the study, they may reflect differing sensitiv-
ities among treating physicians and in the end are a re-
flection of the “real world”. An important part of this
real world is meningitis of unknown origin which is the
most diagnosis-challenging ABM. We had strict criteria
for this diagnosis, and when reasonable doubts arose,
the case was not included in our series.
Changes in population structure contribute to changes
in the spectrum of ABM. During the study period,
Barcelona population has ranged from 1,754,900
Figure 1 Survival curves for adult patients with acute bacterial
meningitis according to age (P = 0.007).
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mum of 1,508,805 in 1996 [28]. However, the elderly
population increased from 252,415 inhabitants in 1986
to 419,988 in 2006, whereas the population aged 15–24
years decreased from 266,791 in 1986 to 157,737 in 2006
[28]. Therefore, a decrease in the population more prone
to meningococcal meningitis was observed together with
an increase in the population more susceptible to having
pneumococcal and listerial meningitis. Surprisingly,
meningitis of unknown origin also significantly increased
in group II, which may be explained by a higher preva-
lence of out-of-hospital antibiotic therapy among elderlyTable 5 Outcome of acute bacterial meningitis according to a
Group I (non-elderly)
N = 427
Type of complication (%)
None (%) 3/292 (1.03)
Neurologic complications (%) 9/26 (34.6)
Extra-neurologic complications (%) 8/55 (14.5)
Both types (%) 30/54 (55.5)
Extra-neurologic complications (%)
New focal neurologic signs (%) 13/23 (56.5)
Coma (%) 37/57 (64.9)
Seizures (%) 16/46 (34.8)
New cranial palsies (%) 4/17 (23.5)
Extra-neurologic complications (%)
Septic shock (%) 30/65 (46.1)
Acute respiratory failure (%) 22/60 (36.7)
Acute renal failure (%) 19/40 (47.5)
Consumption coagulopathy (%) 19/39 (48.7)
Values expressed as patients who died/total number of patients with complication.people. The negative impact of pre-admission antibiotic
therapy on the positivity of microbiological tests is well
known [12,29].
Although N. meninigitidis is not a common cause of
ABM in elderly patients, our epidemiological environment
has for many years been one of high endemicity of menin-
gococcal disease [24,30,31]. Moreover, the incidence of
disease due to serogroup C meningococci increased in
Spain from the mid-nineties [32]. This change of pattern
led to the carrying out of a mass vaccination campaign
against serogroup C in Spain and to inclusion of the men-
ingococcal C conjugate vaccine in the routine vaccination
schedule [33]. Since group C meningococci have a predi-
lection for causing disease in older adults [12], the vaccin-
ation campaign may also have contributed to the
decreased incidence of meningococcal meningitis among
the elderly as our results show. This can be explained by
the increase in herd immunity [34].
With respect to clinical findings, although elderly
patients were brought to the hospital not later than
younger ones, the time before first antibiotic dose was sig-
nificantly longer. There are a cluster of circumstances that
may explain this finding; elderly patients had taken out-of-
hospital antibiotic therapy more frequently, and this, to-
gether with being older, makes the symptoms and signs of
ABM subtler, as exemplified by the less frequent presence
of symptoms and/or signs of ABM and skin lesions
[15,29,35-38], which may eventually lead to a diagnostic
delay. But, above all, elderly patients had a cerebral CT
performed more frequently, and this delayed the spinal
tap and consequently the start of antibiotic therapy. Delayge group and severity indexes*
Group II (elderly) RR (95% CI) P
valueN = 208
3/93 (3.2) 3.07 (0.63–14.97) 0.3263
11/21 (52.4) 1.34 (0.64–2.80) 0.6124
11/51 (29.4) 1.79 (0.82–3.93) 0.2085
33/43 (76.7) 1.22 (0.83–1.79) 0.4041
11/16 (68.7) 1.13 (0.60–2.12) 0.9105
41/48 (85.4) 1.17 (0.84–1.64) 0.4429
21/33 (63.6) 1.51 (0.88–2.58) 0.1908
11/17 (64.7) 2.06 (0.76–5.58) 0.2270
23/35 (74.3) 1.35 (0.89–2.04) 0.2178
27/46 (58.7) 1.38 (0.86–2.20) 0.2360
27/48 (56.2) 1.12 (0.69–1.80) 0.7823
11/15 (73.3) 1.29 (0.72–2.31) 0.5497
*A patient may have more than one complication or sequelae.
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http://www.biomedcentral.com/1471-2334/13/108in starting antibiotic therapy has been advocated as a main
factor in ABM-driven mortality [36-42]. Therefore, a high
index of suspicion of ABM is needed in elderly patients
with fever and CNS dysfunction to rule out meningeal in-
fection eventually leading to a prompt spinal tap and early
starting of empiric antibiotic therapy.
There were no differences between both groups in
terms of CSF parameters except for a higher CSF protein
content for group II patients, which is most likely due to
the predominance of pneumococcal, listerial and gram-
negative bacillary meningitis in this group. We know
that these meningitis have a higher CSF protein content
than meningococcal which predominates among group I
patients (data not shown). Underlying immune suppres-
sion may cause changes in CSF parameters; and we
found like Erdem et al. [37] lower CSF counts in im-
munosuppressed patients but not a different CSF/blood
glucose ratio. In addition, the diagnostic yield of CSF
Gram-stained smear was inferior in elderly patients, but
we must take into account that pre-admission antibiotic
therapy had been taken by 37% of patients, and we know
that this is the most frequent cause of meningitis with
negative CSF Gram-stained smears [35,43,44].
Both neurologic and extra-neurologic complications
appeared more frequently in elderly patients. This may be
explained by two facts; first, the physiological reserve and
the ability of many organs and systems to respond to
insults decrease with age, and second, in elderly patients,
the baseline organ function may be compromised because
of prior co-morbid conditions. Therefore, ABM and/or its
associated systemic consequences may further damage an
already dysfunctional organ, eventually leading to its fail-
ure. However, once present, they usually convey high mor-
tality rates both in young and elder patients. The excess
mortality of ABM in elderly people is a usual finding in
related literature [37,38,44,45]. In fact, this difference in
mortality rate is mainly driven by an excess mortality in
pneumococcal and meningitis of unknown origin.
Conclusions
In summary, elderly people are at higher risk of having
ABM than younger adults, ABM appears more frequently
in patients with co-morbid conditions, is associated with a
longer interval from admission to antibiotic therapy, is
caused by S. pneumoniae, and patients develop neurologic
and extra-neurologic complications more frequently.
ABM in elderly patients is associated with an earlier and
higher mortality rate than in younger ones.
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